 CAMBRIDGE, Mass. MONTREAL--BUSINESS WIRE--Repare Therapeutics Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 12 TRESR Treatment Enabled by SNIPRx trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR Ataxia-Telangiectasia and Rad3-related protein kinase, as well as two additional poster presentations at the 